Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar;46(3):775-9.
doi: 10.1161/STROKEAHA.114.007752. Epub 2015 Jan 15.

Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis

Helmi L Lutsep  1 , Stanley L Barnwell  2 , Darren T Larsen  2 , Michael J Lynn  2 , Mindy Hong  2 , Tanya N Turan  2 , Colin P Derdeyn  2 , David Fiorella  2 , L Scott Janis  2 , Marc I Chimowitz  2 ; SAMMPRIS Investigators
Affiliations
Randomized Controlled Trial

Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis

Helmi L Lutsep et al. Stroke. 2015 Mar.

Abstract

Background and purpose: Stenting has been used as a rescue therapy in patients with intracranial arterial stenosis and a transient ischemic attack or stroke when on antithrombotic therapy (AT). We determined whether the stenting versus aggressive medical therapy for intracranial arterial stenosis (SAMMPRIS) trial supported this approach by comparing the treatments within subgroups of patients whose qualifying event (QE) occurred on versus off of AT.

Methods: The primary outcome, 30-day stroke and death and later strokes in the territory of the qualifying artery, was compared between (1) percutaneous transluminal angioplasty and stenting plus aggressive medical therapy (PTAS) versus aggressive medical management therapy alone (AMM) for patients whose QE occurred on versus off AT and between (2) patients whose QE occurred on versus off AT separately for the treatment groups.

Results: Among the 284/451 (63%) patients who had their QE on AT, the 2-year primary end point rates were 15.6% for those randomized to AMM (n=140) and 21.6% for PTAS (n=144; P=0.043, log-rank test). In the 167 patients not on AT, the 2-year primary end point rates were 11.6% for AMM (n=87) and 18.8% for PTAS (n=80; P=0.31, log-rank test). Within both treatment groups, there was no difference in the time to the primary end point between patients who were on or off AT (AMM, P=0.96; PTAS, P=0.52; log-rank test).

Conclusions: SAMMPRIS results indicate that the benefit of AMM over PTAS is similar in patients on versus off AT at the QE and that failure of AT is not a predictor of increased risk of a primary end point.

Clinical trial registration url: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.

Keywords: antiplatelet agents; intracranial arteriosclerosis; stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves for the primary endpoint in the two treatment groups for patients taking an antithrombotic at the time of the qualifying event.
Figure 2
Figure 2
Kaplan-Meier curves for the primary endpoint in the two treatment groups for patients taking aspirin and clopidogrel at the time of the qualifying event.
Figure 3
Figure 3
Kaplan-Meier curves for the primary endpoint in the two treatment groups for patients not taking an antithrombotic at the time of the qualifying event.
See this image and copyright information in PMC

References

    1. Turan TN, Maidan L, Cotsonis G, Lynn MJ, Romano JG, Levine SR, et al. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009;40:505–509. - PMC - PubMed
    1. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. the SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993–1003. - PMC - PubMed
    1. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Lancet. 2014;383:333–341. - PubMed
    1. Turan TN, Lynn MJ, Nizam A, Lane B, Egan BM, Le NA, et al. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes. 2012;5:e51–e60. - PMC - PubMed
    1. Waters MF, Hoh BL, Lynn MJ, Turan TN, Derdeyn CP, Fiorella D, et al. Risk factors associated with failure of aggressive medical therapy in the SAMMPRIS trial. Stroke. 2014;45:A78. Abstract.

Publication types

Substances

Associated data